The Role of Small Interfering RNAs in Hepatocellular Carcinoma

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2023 Jul 11

PMID 37432548

Authors

Feng Chen

Wang Zhang

Xinran Gao

Hui Yuan

Kehai Liu

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC), a primary liver cancer with high mortality, is the most common malignant tumor in the world. Currently, the effect of routine treatment is poor, especially for this kind of cancer with strong heterogeneity and late detection. In the past decades, the researches of gene therapy for HCC based on small interfering RNA have blossomed everywhere. This is a promising therapeutic strategy, but the application of siRNA is limited by the discovery of effective molecular targets and the delivery system targeting HCC. As the deepening of research, scientists have developed many effective delivery systems and found more new therapeutic targets.

Conclusions: This paper mainly reviews the research on HCC treatment based on siRNA in recent years, and summarizes and classifies the HCC treatment targets and siRNA delivery systems.

Citing Articles

Transarterial Chemoembolization Plus Sorafenib versus Transarterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses and Systematic Reviews.

Yan J, Wen Y, Deng M, Ye B, Liu X, Zhang L J Hepatocell Carcinoma. 2023; 10:1723-1733.

PMID: 37817915 PMC: 10561755. DOI: 10.2147/JHC.S429352.

References

Hajiasgharzadeh K, Somi M, Shanehbandi D, Mokhtarzadeh A, Baradaran B . Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma. J Cell Physiol. 2018; 234(4):3263-3276. DOI: 10.1002/jcp.27015. View

Lee S, Kim M, Kwon I, Roberts T . Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev. 2016; 104:2-15. PMC: 4958528. DOI: 10.1016/j.addr.2016.05.010. View

Farra R, Grassi M, Grassi G, Dapas B . Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma. World J Gastroenterol. 2015; 21(30):8994-9001. PMC: 4533033. DOI: 10.3748/wjg.v21.i30.8994. View

Varshosaz J, Farzan M . Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol. 2015; 21(42):12022-41. PMC: 4641122. DOI: 10.3748/wjg.v21.i42.12022. View

Longerich T . [Hepatocellular carcinoma]. Pathologe. 2020; 41(5):478-487. DOI: 10.1007/s00292-020-00801-z. View

Hwang L . Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci. 2006; 13(4):453-68. DOI: 10.1007/s11373-006-9085-7. View

Xu C, Lee S, Chen X . RNA interference as therapeutics for hepatocellular carcinoma. Recent Pat Anticancer Drug Discov. 2010; 6(1):106-15. DOI: 10.2174/157489211793980097. View

Li X, Li J, Li C, Guo Q, Wu M, Su L . Aminopeptidase N-targeting nanomolecule-assisted delivery of VEGF siRNA to potentiate antitumour therapy by suppressing tumour revascularization and enhancing radiation response. J Mater Chem B. 2021; 9(36):7530-7543. DOI: 10.1039/d1tb00990g. View

Xia Y, Wang C, Xu T, Li Y, Guo M, Lin Z . Targeted delivery of HES5-siRNA with novel polypeptide-modified nanoparticles for hepatocellular carcinoma therapy. RSC Adv. 2022; 8(4):1917-1926. PMC: 9077277. DOI: 10.1039/c7ra12461a. View

10.

Xia Y, Tang G, Chen Y, Wang C, Guo M, Xu T . Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma. Bioact Mater. 2020; 6(5):1330-1340. PMC: 7658325. DOI: 10.1016/j.bioactmat.2020.10.019. View

11.

Zhang J, Ma H, Yang L, Yang H, He Z . Silencing of the gene suppresses proliferation and invasion of hepatocellular carcinoma HepG2 cells. J Int Med Res. 2019; 47(3):1319-1329. PMC: 6421384. DOI: 10.1177/0300060518822913. View

12.

Liu Y, Tan M, Fang C, Chen X, Liu H, Feng Y . A novel multifunctional gold nanorod-mediated and tumor-targeted gene silencing of GPC-3 synergizes photothermal therapy for liver cancer. Nanotechnology. 2021; 32(17):175101. DOI: 10.1088/1361-6528/abdbed. View

13.

Zhao B, Zhou B, Shi K, Zhang R, Dong C, Xie D . Sustained and targeted delivery of siRNA/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy. Cancer Sci. 2021; 112(6):2481-2492. PMC: 8177784. DOI: 10.1111/cas.14903. View

14.

Zhang M, Weng Y, Cao Z, Guo S, Hu B, Lu M . ROS-Activatable siRNA-Engineered Polyplex for NIR-Triggered Synergistic Cancer Treatment. ACS Appl Mater Interfaces. 2020; 12(29):32289-32300. DOI: 10.1021/acsami.0c06614. View

15.

Khan A, Alanazi A, Jabeen M, Chauhan A, Ansari M . Therapeutic potential of functionalized siRNA nanoparticles on regression of liver cancer in experimental mice. Sci Rep. 2019; 9(1):15825. PMC: 6825139. DOI: 10.1038/s41598-019-52142-4. View

16.

Liu Y, Tan M, Zhang Y, Huang W, Min L, Peng S . Targeted Gene Silencing BRAF Synergized Photothermal Effect Inhibits Hepatoma Cell Growth Using New GAL-GNR-siBRAF Nanosystem. Nanoscale Res Lett. 2020; 15(1):116. PMC: 7246281. DOI: 10.1186/s11671-020-03340-x. View

17.

Guo Y, Wu Z, Shen S, Guo R, Wang J, Wang W . Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy. Nat Commun. 2018; 9(1):3430. PMC: 6109108. DOI: 10.1038/s41467-018-05764-7. View

18.

Vivero-Escoto J, Vadarevu H, Juneja R, Schrum L, Benbow J . Nanoparticle mediated silencing of tenascin C in hepatic stellate cells: effect on inflammatory gene expression and cell migration. J Mater Chem B. 2019; 7(46):7396-7405. DOI: 10.1039/c9tb01845j. View

19.

Woitok M, Zoubek M, Doleschel D, Bartneck M, Mohamed M, Kiessling F . Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease. Cell Death Dis. 2020; 11(5):343. PMC: 7214425. DOI: 10.1038/s41419-020-2571-4. View

20.

Xiang-Chun D, Xiao-Qing Y, Ting-Ting Y, Zhen-Hui L, Xiao-Yan L, Xia L . Alpha-enolase regulates hepatitis B virus replication through suppression of the interferon signalling pathway. J Viral Hepat. 2017; 25(3):289-295. DOI: 10.1111/jvh.12813. View